CDMO Archives | BioInformant

Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges

April 16, 2026 By BioInformant Team Leave a Comment

Backed by a €12M Bpifrance grant, the program builds a GMP-compatible manufacturing platform for iPSC-derived cell therapies — directly applicable to biotech and pharma iPSC programs.

Toulouse, 2026 April 16^th– Scale-up remains one of the most critical unsolved challenges in iPSC-derived cell therapy. Despite strong clinical promise, most manufacturing processes today can only supply material for a very limited number of patients — a bottleneck that limits clinical progression and commercial viability across the field. [Read more…]

CHU Toulouse and Cell-Easy Launch A-MUSE, a Phase 1/2 Clinical Trial Evaluating the CellReady® Allogeneic MSC Platform in Systemic Sclerosis

January 22, 2026 By BioInformant Team Leave a Comment

Toulouse, January 22, 2026 — Cell-Easy, a CDMO specialized in the development and GMP manufacturing of Advanced Therapy Medicinal Products (ATMPs), announces a new clinical milestone achieved in close collaboration with Toulouse University Hospital (CHU Toulouse). The European Medicines Agency (EMA) has granted Clinical Trial Authorization (CTA) for AMUSE, a Phase 1/2 clinical trial evaluating the safety and efficacy of an allogeneic mesenchymal stromal cell (MSC) therapy in patients with systemic sclerosis presenting perioral fibrosis and functional impairment. [Read more…]

Cellistic Launches Three New iPSC-based GMP Manufacturing Platforms to advance Immuno-Oncology and Regenerative Cell Therapies

January 13, 2026 By BioInformant Team Leave a Comment

Belgium, Mont Saint-Guibert, 13 January 2026 – Cellistic, a global leader in allogeneic iPSC-derived cell therapy manufacturing, today announced the launch of three new iPSC-derived GMP cell therapy manufacturing platforms: Echo™-T, Echo™-Cardio, and Echo™-Endothelial. The new platforms are designed to advance cell therapies and drive progress across immuno-oncology and regenerative medicine.Building on the success of the Cellistic Echo™-NK manufacturing platform for natural killer (NK) cells, the expanded Cellistic Echo™ portfolio leverages the company’s GMP manufacturing expertise and its EMA-certified, FDA- and PMDA-compliant manufacturing facility. Through dedicated platform development, these capabilities are extended to deliver scalable solutions across additional immune and regenerative cell types.
[Read more…]

Vector BioMed Expands LENTIVERSE™ Platform and Unveils New Brand Identity to Close the Gap Between CGT Innovation and Patient Access

November 14, 2025 By BioInformant Team Leave a Comment

The expansion of LENTIVERSE™ platform introduces “One Lentiviral Vector Platform, Two Paths to Advance Cures,” aligning scientific rigor with transparent economics and global accessibility.

GAITHERSBURG, Md., Nov. 6, 2025 — Vector BioMed, a leading lentiviral vector supplier and contract vector development and manufacturing organization (CVDMO), today announced the expansion of its LENTIVERSE™ platform alongside the unveiling of its new brand identity, designed to accelerate global gene therapy access by providing custom and ready-to-deploy solutions. This expansion strengthens the company’s mission to make gene therapies more accessible and cost-effective for patients worldwide. [Read more…]

Bridging the Gap: Streamlining iPSC-Derived Cell Line Development from Donor Cells to MCB

November 14, 2025 By BioInformant Team Leave a Comment

Allogeneic iPSC-derived therapies hold immense promise, offering scalable, off-the-shelf solutions for a wide spectrum of diseases. However, the journey from donor cells to a gene edited, clinically compliant GMP Master Cell Bank (MCB) is fraught with challenges and is particularly vulnerable to risks stemming from misaligned early development.

A major bottleneck seen in the majority of iPSC therapeutic programs arises when development teams continue to rely on R&D grade cell lines to confirm proof-of-concept, conduct preclinical animal studies, and to start process & analytical development. [Read more…]